Scandinavian ChemoTech AB (publ) (CMOTEC-B.ST)
SEK 1.48
(0.68%)
SEK 1.48
(0.68%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.65 Million SEK | -36516.36% |
| 2022 | -55 Thousand SEK | -117.03% |
| 2021 | 323 Thousand SEK | 2407.14% |
| 2020 | -14 Thousand SEK | -104.26% |
| 2019 | 329 Thousand SEK | 8.94% |
| 2018 | 302 Thousand SEK | 103.65% |
| 2017 | -8.27 Million SEK | -518.66% |
| 2016 | 1.97 Million SEK | 32780.31% |
| 2015 | 6013.00 SEK | 121.37% |
| 2014 | -28.13 Thousand SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -3.74 Million SEK | -33.62% |
| 2024 Q1 | -2.79 Million SEK | 47.16% |
| 2023 Q2 | -5.95 Million SEK | -21.68% |
| 2023 Q4 | -5.29 Million SEK | -32.72% |
| 2023 FY | -20.13 Million SEK | -36516.36% |
| 2023 Q1 | -4.89 Million SEK | -1526.25% |
| 2023 Q3 | -3.99 Million SEK | 32.99% |
| 2022 Q2 | -5.75 Million SEK | -29.44% |
| 2022 FY | -55 Thousand SEK | -117.03% |
| 2022 Q4 | -301 Thousand SEK | 93.71% |
| 2022 Q3 | -4.78 Million SEK | 16.91% |
| 2022 Q1 | -4.44 Million SEK | 17.72% |
| 2021 FY | 323 Thousand SEK | 2407.14% |
| 2021 Q1 | 943 Thousand SEK | 393.72% |
| 2021 Q2 | 1.31 Million SEK | 39.55% |
| 2021 Q3 | 153 Thousand SEK | -88.37% |
| 2021 Q4 | -5.4 Million SEK | -3633.99% |
| 2020 Q2 | 752 Thousand SEK | 59.32% |
| 2020 FY | -14 Thousand SEK | -104.26% |
| 2020 Q3 | 398 Thousand SEK | -47.07% |
| 2020 Q1 | 472 Thousand SEK | -15.11% |
| 2020 Q4 | 191 Thousand SEK | -52.01% |
| 2019 FY | 329 Thousand SEK | 8.94% |
| 2019 Q2 | 1.92 Million SEK | 69.25% |
| 2019 Q4 | 556 Thousand SEK | -31.86% |
| 2019 Q1 | 1.13 Million SEK | 2292.04% |
| 2019 Q3 | 816 Thousand SEK | -57.52% |
| 2018 Q3 | 21.74 Thousand SEK | -19.31% |
| 2018 FY | 302 Thousand SEK | 103.65% |
| 2018 Q4 | 47.44 Thousand SEK | 118.23% |
| 2018 Q2 | 26.94 Thousand SEK | -97.33% |
| 2018 Q1 | 1.01 Million SEK | 0.0% |
| 2017 Q1 | 20.34 Thousand SEK | -97.4% |
| 2017 FY | -8.27 Million SEK | -518.66% |
| 2017 Q3 | 547.91 Thousand SEK | 16.94% |
| 2017 Q2 | 468.53 Thousand SEK | 2203.39% |
| 2016 Q1 | 12.35 Thousand SEK | -93.17% |
| 2016 FY | 1.97 Million SEK | 32780.31% |
| 2016 Q4 | 783.5 Thousand SEK | 179.03% |
| 2016 Q2 | 1 Million SEK | 8006.01% |
| 2016 Q3 | 280.8 Thousand SEK | -71.95% |
| 2015 Q4 | 180.86 Thousand SEK | 100.0% |
| 2015 Q3 | 90.43 Thousand SEK | 0.0% |
| 2015 FY | 6013.00 SEK | 121.37% |
| 2014 FY | -28.13 Thousand SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 101.032% |
| Ziccum AB (publ) | -23.28 Million SEK | 107.12% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 99.521% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 96.032% |
| Mendus AB (publ) | 28.48 Million SEK | 94.18% |
| Genovis AB (publ.) | 54 Million SEK | 96.93% |
| Intervacc AB (publ) | -13.79 Million SEK | 112.02% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 23.63% |
| Active Biotech AB (publ) | -1.67 Million SEK | 198.985% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 83.358% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 93.818% |
| Aptahem AB (publ) | 2.63 Million SEK | 36.974% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 148.465% |
| Kancera AB (publ) | -1.96 Million SEK | 184.377% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -2053.247% |
| Fluicell AB (publ) | 1.73 Million SEK | 4.603% |
| Saniona AB (publ) | 11.78 Million SEK | 85.926% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 132.402% |
| Biovica International AB (publ) | 6.87 Million SEK | 75.891% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 107.121% |
| AcouSort AB (publ) | 8.38 Million SEK | 80.236% |
| Xintela AB (publ) | 78 Thousand SEK | -2025.641% |
| Abliva AB (publ) | -35.66 Million SEK | 104.649% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 101.129% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 40.933% |
| OncoZenge AB (publ) | 3000.00 SEK | -55166.667% |
| Amniotics AB (publ) | -1.93 Million SEK | 185.907% |
| 2cureX AB (publ) | -37.48 Million SEK | 104.423% |
| CombiGene AB (publ) | -21.29 Million SEK | 107.787% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 491.962% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 99.853% |
| Camurus AB (publ) | 1.58 Billion SEK | 99.895% |
| Corline Biomedical AB | 28.38 Million SEK | 94.158% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 101.351% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 104.818% |
| I-Tech AB | 27.56 Million SEK | 93.985% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 97.663% |
| Cyxone AB (publ) | 2.61 Million SEK | 36.499% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 51.278% |
| Biosergen AB | -456 Thousand SEK | 463.596% |
| Cantargia AB (publ) | -3.45 Million SEK | 148.044% |
| NextCell Pharma AB | -43.74 Million SEK | 103.79% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 118.034% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 85.221% |
| Nanologica AB (publ) | -76 Thousand SEK | 2281.579% |
| SynAct Pharma AB | -778 Thousand SEK | 313.111% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 959.067% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 112.831% |
| Lipum AB (publ) | 53 Thousand SEK | -3028.302% |
| BioInvent International AB (publ) | 71.46 Million SEK | 97.68% |
| Alzinova AB (publ) | 19.87 Million SEK | 91.657% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 95.432% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -13.327% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 11153.333% |
| Simris Alg AB (publ) | 2 Million SEK | 17.389% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 146.313% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 95.315% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 258.055% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 47.079% |